Bladder drugs and risk of dementia: Danish nationwide active comparator study DOI Creative Commons
Nelsan Pourhadi, Janet Janbek, Christiane Gasse

и другие.

BMJ Medicine, Год журнала: 2025, Номер 4(1), С. e001125 - e001125

Опубликована: Фев. 1, 2025

To assess the association between cumulative use of anticholinergic bladder drugs and risk all cause dementia compared with non-use β3 agonist drug, mirabegron. Danish nationwide active comparator study. National registries, 1 January 2000 to 31 December 2022. 29 254 individuals were matched by age sex 646 270 controls without dementia, identified from a cohort 2.26 million aged 60-75 years 2022 no previous dementia. Two separate nested case-control populations studied: general population an 58 242 new users (2198 developed 10 990 controls). Information on medication was based filled prescriptions defined daily doses. Conditional logistic regression provided incidence rate ratios for associations mirabegron adjusted educational level, cardiovascular disease, diabetes, hypertension, dyslipidaemia, Charlson Comorbidity Index. Compared non-use, ever associated increased ratio 1.44 (95% confidence interval (CI) 1.40 1.48). The increasing drug use, 1.31 CI 1.27 1.36) 1-90 doses 1.68 (1.59 1.76) >365 types dementia: tolterodine 1.43 1.38 1.49), solifenacin 1.37 (1.29 1.46), trospium 1.52 (1.37 1.67), fesoterodine 1.48 (1.26 1.74). not seen when directly (incidence 0.82, 95% 0.74 0.92), irrespective type drug. In this study, but applying These findings highlight relevance using comparator. Future research should evaluate cognitive impairment both drugs.

Язык: Английский

Effectiveness of breathing exercises on urinary symptoms, muscle activity, and strength in women with multiple sclerosis and urinary incontinence—a study protocol for a randomized controlled trial study DOI Creative Commons

Atieh Nazem,

Shabnam ShahAli,

Mehdi Dadgoo

и другие.

Trials, Год журнала: 2025, Номер 26(1)

Опубликована: Янв. 17, 2025

Urinary incontinence (UI) is a common and debilitating condition among people with multiple sclerosis (MS) more prevalent women. Over the past decade, numerous studies have investigated effects of pelvic floor muscle training (PFMT) as treatment for UI in MS. MS negatively impacts pulmonary function even early stages disease may experience respiratory weakness. Considering synergy between (PFM) muscles, this trial will evaluate PFMT breathing exercises on PFM activity strength, diaphragm activity, urinary symptoms women who UI. Fifty participate parallel randomized controlled trial, comprising 32 sessions. The intervention group consists exercises, control includes PFMT. severity symptoms, strength be evaluated using International Consultation Incontinence Questionnaire–Urinary Short Form, ultrasound imaging, modified Oxford grading scale, respectively before after intervention. current designed to examine combined exercise program It hypothesized that conjunction improve patient compared alone. was registered Iranian Registry Clinical Trials code IRCT20180916041051N3 approved 23 May 2024.

Язык: Английский

Процитировано

1
Bladder drugs and risk of dementia: Danish nationwide active comparator study DOI Creative Commons
Nelsan Pourhadi, Janet Janbek, Christiane Gasse

и другие.

BMJ Medicine, Год журнала: 2025, Номер 4(1), С. e001125 - e001125

Опубликована: Фев. 1, 2025

To assess the association between cumulative use of anticholinergic bladder drugs and risk all cause dementia compared with non-use β3 agonist drug, mirabegron. Danish nationwide active comparator study. National registries, 1 January 2000 to 31 December 2022. 29 254 individuals were matched by age sex 646 270 controls without dementia, identified from a cohort 2.26 million aged 60-75 years 2022 no previous dementia. Two separate nested case-control populations studied: general population an 58 242 new users (2198 developed 10 990 controls). Information on medication was based filled prescriptions defined daily doses. Conditional logistic regression provided incidence rate ratios for associations mirabegron adjusted educational level, cardiovascular disease, diabetes, hypertension, dyslipidaemia, Charlson Comorbidity Index. Compared non-use, ever associated increased ratio 1.44 (95% confidence interval (CI) 1.40 1.48). The increasing drug use, 1.31 CI 1.27 1.36) 1-90 doses 1.68 (1.59 1.76) >365 types dementia: tolterodine 1.43 1.38 1.49), solifenacin 1.37 (1.29 1.46), trospium 1.52 (1.37 1.67), fesoterodine 1.48 (1.26 1.74). not seen when directly (incidence 0.82, 95% 0.74 0.92), irrespective type drug. In this study, but applying These findings highlight relevance using comparator. Future research should evaluate cognitive impairment both drugs.

Язык: Английский

Процитировано

0